NVO vs. SNY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NVO and SNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both NVO and SNY are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.
| Symbol | NVO | SNY |
|---|---|---|
| Company Name | Novo Nordisk A/S | Sanofi |
| Country | Denmark | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 216.69 billion USD | 127.74 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | April 30, 1981 | July 1, 2002 |
| Security Type | ADR | ADR |
Historical Performance
This chart compares the performance of NVO and SNY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NVO | SNY |
|---|---|---|
| 5-Day Price Return | 5.55% | 0.94% |
| 13-Week Price Return | -10.49% | 3.93% |
| 26-Week Price Return | -29.53% | -3.88% |
| 52-Week Price Return | -59.81% | -1.08% |
| Month-to-Date Return | -1.55% | 2.61% |
| Year-to-Date Return | -50.17% | -4.11% |
| 10-Day Avg. Volume | 8.31M | 1.47M |
| 3-Month Avg. Volume | 7.13M | 1.85M |
| 3-Month Volatility | 44.27% | 28.76% |
| Beta | 1.58 | 1.08 |
Profitability
Return on Equity (TTM)
NVO
66.95%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
NVO’s Return on Equity of 66.95% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
SNY
18.76%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
SNY’s Return on Equity of 18.76% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
NVO
32.88%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 32.88% places NVO in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
SNY
20.66%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 20.66% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
NVO
42.03%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
An Operating Profit Margin of 42.03% places NVO in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
SNY
20.74%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
SNY’s Operating Profit Margin of 20.74% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | NVO | SNY |
|---|---|---|
| Return on Equity (TTM) | 66.95% | 18.76% |
| Return on Assets (TTM) | 21.29% | 10.65% |
| Net Profit Margin (TTM) | 32.88% | 20.66% |
| Operating Profit Margin (TTM) | 42.03% | 20.74% |
| Gross Profit Margin (TTM) | 82.05% | 72.29% |
Financial Strength
Current Ratio (MRQ)
NVO
0.78
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
SNY
1.06
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
SNY’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
NVO
0.60
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
NVO’s Debt-to-Equity Ratio of 0.60 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SNY
0.30
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.30 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
NVO
149.07
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | NVO | SNY |
|---|---|---|
| Current Ratio (MRQ) | 0.78 | 1.06 |
| Quick Ratio (MRQ) | 0.57 | 0.30 |
| Debt-to-Equity Ratio (MRQ) | 0.60 | 0.30 |
| Interest Coverage Ratio (TTM) | 149.07 | 22.06 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NVO
3.77%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.77%, NVO offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
SNY
4.40%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 4.40%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
NVO
68.98%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
NVO’s Dividend Payout Ratio of 68.98% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
SNY
52.56%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | NVO | SNY |
|---|---|---|
| Dividend Yield (TTM) | 3.77% | 4.40% |
| Dividend Payout Ratio (TTM) | 68.98% | 52.56% |
Valuation
Price-to-Earnings Ratio (TTM)
NVO
13.31
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.31 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
SNY
7.90
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 7.90 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
NVO
4.38
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
NVO’s P/S Ratio of 4.38 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SNY
1.63
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, SNY’s P/S Ratio of 1.63 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
NVO
6.88
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
NVO’s P/B Ratio of 6.88 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
SNY
1.32
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
SNY’s P/B Ratio of 1.32 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | NVO | SNY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.31 | 7.90 |
| Price-to-Sales Ratio (TTM) | 4.38 | 1.63 |
| Price-to-Book Ratio (MRQ) | 6.88 | 1.32 |
| Price-to-Free Cash Flow Ratio (TTM) | 21.18 | 10.85 |